Dyne Therapeutics, Inc. (NASDAQ:DYN) Stake Cut by Fcpm Iii Services B.V.

Fcpm Iii Services B.V. decreased its holdings in Dyne Therapeutics, Inc. (NASDAQ:DYN) by 8.3% in the fourth quarter, Holdings Channel reports. The firm owned 5,462,846 shares of the company’s stock after selling 491,223 shares during the period. Dyne Therapeutics comprises about 21.8% of Fcpm Iii Services B.V.’s portfolio, making the stock its 2nd largest position. Fcpm Iii Services B.V. owned about 0.05% of Dyne Therapeutics worth $128,705,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in DYN. Geode Capital Management LLC increased its position in shares of Dyne Therapeutics by 1.5% in the 4th quarter. Geode Capital Management LLC now owns 1,887,329 shares of the company’s stock valued at $44,476,000 after acquiring an additional 27,916 shares during the period. Norges Bank acquired a new position in Dyne Therapeutics in the 4th quarter worth approximately $22,384,000. ArrowMark Colorado Holdings LLC boosted its holdings in shares of Dyne Therapeutics by 3.6% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 932,231 shares of the company’s stock valued at $21,963,000 after acquiring an additional 32,041 shares during the last quarter. Northern Trust Corp increased its stake in shares of Dyne Therapeutics by 7.7% in the fourth quarter. Northern Trust Corp now owns 777,013 shares of the company’s stock worth $18,306,000 after acquiring an additional 55,511 shares during the period. Finally, Braidwell LP acquired a new position in Dyne Therapeutics during the fourth quarter valued at $16,049,000. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

DYN has been the topic of several analyst reports. BMO Capital Markets started coverage on Dyne Therapeutics in a research report on Wednesday, March 12th. They set an “outperform” rating and a $50.00 price target on the stock. Scotiabank initiated coverage on Dyne Therapeutics in a research report on Friday, March 7th. They issued a “sector outperform” rating and a $50.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and issued a $46.00 target price on shares of Dyne Therapeutics in a research note on Monday, March 17th. JPMorgan Chase & Co. cut their price objective on shares of Dyne Therapeutics from $18.00 to $17.00 and set a “neutral” rating for the company in a report on Friday, March 21st. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $45.00 target price on shares of Dyne Therapeutics in a research note on Tuesday, January 14th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $47.46.

Dyne Therapeutics Stock Up 20.4 %

NASDAQ:DYN opened at $11.32 on Friday. Dyne Therapeutics, Inc. has a 52 week low of $6.36 and a 52 week high of $47.45. The stock’s fifty day moving average is $10.38 and its two-hundred day moving average is $18.32. The stock has a market capitalization of $1.29 billion, a price-to-earnings ratio of -3.18 and a beta of 1.19.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Thursday, May 8th. The company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.88) by ($0.17). On average, sell-side analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total value of $36,242.10. Following the sale, the insider now owns 199,087 shares of the company’s stock, valued at $2,777,263.65. This trade represents a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders have sold a total of 6,237 shares of company stock worth $77,760 in the last ninety days. 20.77% of the stock is owned by corporate insiders.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.